Evidence map›Paper›PMID 42376261›Full record

ReviewChem & bio engineering2026

New Frontiers in AI-Nano Converged Platforms for Intelligent Diagnostics, Therapeutics, and Safety Evaluation.

Huijie Zhou, Jiming Xu, Xinyu Qin, Jing Zhang, Wenjiang Zou, Mohsen Shakouri, Jun Wu, Lvzhou Li, Yuping Li, Jianning Ding and 1 more

Abstract readReview
In one paragraph

Review in Chem & bio engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huijie ZhouInstitute of Technology for Carbon Neutralization, Yangzhou University, Yangzhou 225127, Jiangsu, P. R. China.ORCID https://orcid.org/0009-0000-3016-6915
Jiming XuInstitute of Technology for Carbon Neutralization, Yangzhou University, Yangzhou 225127, Jiangsu, P. R. China.
Xinyu QinSchool of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou, Jiangsu, 225009 P. R. China.
Jing ZhangInstitute of Technology for Carbon Neutralization, Yangzhou University, Yangzhou 225127, Jiangsu, P. R. China.
Wenjiang ZouInstitute of Technology for Carbon Neutralization, Yangzhou University, Yangzhou 225127, Jiangsu, P. R. China.
Mohsen ShakouriCanadian Light Source, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 2V3, Canada.
Jun WuDepartment of Thoracic Surgery, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, 225000, China.
Lvzhou LiInstitute of Technology for Carbon Neutralization, Yangzhou University, Yangzhou 225127, Jiangsu, P. R. China.
Yuping LiDepartment of Neurosurgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, 225000 P. R. China.
Jianning DingInstitute of Technology for Carbon Neutralization, Yangzhou University, Yangzhou 225127, Jiangsu, P. R. China.
Huan PangInstitute of Technology for Carbon Neutralization, Yangzhou University, Yangzhou 225127, Jiangsu, P. R. China.ORCID https://orcid.org/0000-0002-5319-0480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complexity of nanomedicine poses a significant challenge to traditional empirical methods. Machine learning (ML), with its ability to parse high-dimensional data and predict nonlinear interactions, is empowering AI nano fusion platforms, driving innovation in diagnostic and therapeutic evaluation paradigms. This review explores breakthrough applications of ML in core areas of nanomedicine, including intelligent diagnosis (such as ML enhanced nanosensors for high-precision noninvasive cancer early screening), precision therapy (such as closed-loop system driven rational design and delivery optimization of nanomedicine), safety assessment (such as interpretable AI prediction of biological and environmental toxicity of nanomaterials), and clinical translation (to address scientific challenges related to standardization, reproducibility, and regulatory). The paper provides an in-depth analysis of the key bottlenecks currently facing the transition from laboratory to clinical application, such as batch differences, dynamic interference, and regulatory lag. Based on recent research progress, a future path to achieve an intelligent closed-loop of "design diagnosis and treatment evaluation" is proposed, providing key insights for the development of the next generation of safe and efficient intelligent nanodiagnosis and treatment platforms.

Indexed as

Clinical translationIntelligent diagnosis and treatmentMachine learningNanomedicine

Identifiers

PMID42376261
PMCPMC13312061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.